相似文献
1
Sepsis: Diagnostic and Therapeutic Challenges.
Biomed Res Int. 2016;2016:5786182. doi: 10.1155/2016/5786182. Epub 2016 Oct 17.
2
Year in review in Critical Care, 2004: sepsis and multi-organ failure.
Crit Care. 2005 Aug;9(4):409-13. doi: 10.1186/cc3728. Epub 2005 May 23.
3
Year in review 2007: Critical Care--multiple organ failure and sepsis.
Crit Care. 2008;12(5):228. doi: 10.1186/cc6950. Epub 2008 Oct 14.
4
[Sepsis and multi-organ failure--recognize , understand and treat early].
Anasthesiol Intensivmed Notfallmed Schmerzther. 2015 Feb;50(2):112-3. doi: 10.1055/s-0041-100497. Epub 2015 Feb 27.
5
Hemofiltration in sepsis: where do we go from here?
Crit Care. 2000;4(2):69-71. doi: 10.1186/cc659. Epub 2000 Feb 16.
6
Surgical Critical Care for the Patient with Sepsis and Multiple Organ Dysfunction.
Anesthesiol Clin. 2016 Dec;34(4):681-696. doi: 10.1016/j.anclin.2016.06.005.
7
Metabolic support in sepsis and multiple organ failure.
Crit Care Med. 2007 Sep;35(9 Suppl):S435. doi: 10.1097/01.CCM.0000281832.42767.86.
8
Sepsis strategies in development.
Clin Chest Med. 2008 Dec;29(4):735-47, x-xi. doi: 10.1016/j.ccm.2008.06.007.
9
An unusual case of hiatus hernia contributing to slow respiratory wean in the intensive care unit.
Am J Respir Crit Care Med. 2012 Sep 15;186(6):570-1. doi: 10.1164/ajrccm.186.6.570.
10
The systemic inflammatory response, sepsis, and multiple organ dysfunction: new definitions for an old problem.
Crit Care Nurs Clin North Am. 1994 Jun;6(2):243-50.
引用本文的文献
1
Advancements, Challenges, and Future Prospects of Nanotechnology in Sepsis Therapy.
Int J Nanomedicine. 2025 Jun 16;20:7685-7714. doi: 10.2147/IJN.S488026. eCollection 2025.
2
Recent nanoengineered therapeutic advancements in sepsis management.
Front Bioeng Biotechnol. 2024 Dec 5;12:1495277. doi: 10.3389/fbioe.2024.1495277. eCollection 2024.
3
Whole blood transcriptomics identifies subclasses of pediatric septic shock.
Crit Care. 2023 Dec 8;27(1):486. doi: 10.1186/s13054-023-04689-y.
4
Nanotechnology Applications in Sepsis: Essential Knowledge for Clinicians.
Pharmaceutics. 2023 Jun 8;15(6):1682. doi: 10.3390/pharmaceutics15061682.
5
Sepsis Management, Controversies, and Advancement in Nanotechnology: A Systematic Review.
Cureus. 2022 Feb 11;14(2):e22112. doi: 10.7759/cureus.22112. eCollection 2022 Feb.
6
The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences.
Crit Care Res Pract. 2021 Jul 17;2021:7769516. doi: 10.1155/2021/7769516. eCollection 2021.
7
Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology.
J Biomed Sci. 2021 Jan 8;28(1):6. doi: 10.1186/s12929-020-00702-6.
8
Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.
Int J Mol Sci. 2020 Aug 3;21(15):5543. doi: 10.3390/ijms21155543.
本文引用的文献
1
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
2
Sepsis: From Pathophysiology to Individualized Patient Care.
J Immunol Res. 2015;2015:510436. doi: 10.1155/2015/510436. Epub 2015 Jul 15.
3
Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy.
Cytometry B Clin Cytom. 2016 Jul;90(4):376-86. doi: 10.1002/cyto.b.21270. Epub 2015 Jul 31.
4
Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012.
JAMA. 2014 Apr 2;311(13):1308-16. doi: 10.1001/jama.2014.2637.
5
Benchmarking the incidence and mortality of severe sepsis in the United States.
Crit Care Med. 2013 May;41(5):1167-74. doi: 10.1097/CCM.0b013e31827c09f8.
6
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.
Lancet Infect Dis. 2013 Mar;13(3):260-8. doi: 10.1016/S1473-3099(13)70001-X.
7
We should abandon randomized controlled trials in the intensive care unit.
Crit Care Med. 2010 Oct;38(10 Suppl):S534-8. doi: 10.1097/CCM.0b013e3181f208ac.
8
Epidemiology of sepsis in Germany: results from a national prospective multicenter study.
Intensive Care Med. 2007 Apr;33(4):606-18. doi: 10.1007/s00134-006-0517-7. Epub 2007 Feb 24.
9
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
Crit Care Med. 2006 Jun;34(6):1589-96. doi: 10.1097/01.CCM.0000217961.75225.E9.
10
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group.
Crit Care Med. 1989 May;17(5):389-93.
Zotero 插件